Demand grows for superfast cycler after LABVOLUTION and ESHG showings
Amsterdam, July 12, 2017: Dutch biotechnology company Molecular Biology Systems(MBS) today announced it has signed an exclusive distributor agreement for its revolutionary NEXTGENPCR thermal cycler with Isogen Life Sciences. This follows highly successful showings of the first production models at the recent ESHG and LABVOLUTIONS meetings. The distributorship covers both Benelux, where Isogen has its main office in De Meern (Netherlands), Belgium and Luxembourg and Spain, which is managed from Barcelona and Madrid.
Described as the first real advance in thermal cycling for 15 years, the NEXTGENPCR dramatically slashes current time-consuming DNA amplification from hours to minutes. For example, a 3 Step, 30 cycle protocol can be performed in less than 2 minutes. Standard format 96- or 384 well microplates are used, making incorporation into existing laboratory routines and protocols seamless. NEXTGENPCR delivers these astonishing times by turning existing technology on its head. Instead of heating and cooling down Peltier blocks, NEXTGENPCR cleverly moves standard microplates rapidly across 3 temperature zones already set to the required denaturing, extension and annealing temperatures. The microplate samples are embedded in polypropylene foil and slightly compressed by the temperature blocks in each zone which ensures thorough sample mixing and optimal heat transfer. Well to well uniformity across the block is better than 0.1 °C. Temperature transition is practically instantaneous with estimated ramp rates of 1000 degrees per second and a total reaction time of 2 minutes.
Isogen Life Science provides a wide range of instruments, reagents and consumables in the areas of cell biology, molecular biology and biochemistry. “Our products are used by biotechnology companies and leading research institutes. Therefore, we are delighted to be able to offer NEXTGENPCR to our customers,” says Isogen Managing Director Martin Donker. “With increasing pressure on throughput, we see a real need for speeding up the thermal cycling phase. Furthermore, NEXTGEN is ideal for both small and, with its SILA-protocol and robot-readiness, large facilities.”
“We are delighted to have signed this agreement with such a reputable distributor,” says MBS CEO and founder Gert de Vos. “NEXTGENPCR’s ability to slash amplification times from hours to minutes and fit seamlessly into any lab routines and protocols is gaining major attention around Europe and we hope to complement this deal with other territories in the near future.”
For further information: Gert de Vos, CEO gertdevos@mbspcr.com www.nextgenpcr.com
Media:
Richard Hayhurst
Richard@richardhayhurstassociates.com
Notes to editors:
Molecular Biology Systems (MBS) is a Netherlands-based molecular biology instrumentation company founded in 2015. The company’s lead product is the NEXTGENPCR thermal cycler which uses patented heating and cooling technology to reduce PCR amplification cycles from hours to minutes for both research and routine genetic testing. More at www.nextgenpcr.com
